Iopidine® (Apraclonidine Hydrochloride)

Apraclonidine works by selectively activating alpha‑2 adrenergic receptors in the eye. This reduces the production of aqueous humor and increases uveoscleral outflow, leading to a net decrease in intra‑ocular pressure.

The dosing regimen for Iopidine® is determined by the prescribing clinician based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) as directed, but the exact frequency and duration are individualized.

Safety data for apraclonidine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Iopidine®, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Iopidine® (apraclonidine) is an alpha‑2 agonist, whereas many alternatives such as timolol are beta‑blockers. Apraclonidine primarily reduces aqueous humor production and enhances outflow, while beta‑blockers mainly decrease production. Choice depends on patient tolerance, comorbidities, and desired IOP‑lowering profile.

Iopidine® should be stored at room temperature below 25 °C, in its original container, protected from light and moisture. Do not freeze the solution, and keep the cap tightly closed when not in use.

Iopidine® is administered as an ophthalmic solution. The prescriber instructs the patient to place the recommended number of drops into the affected eye(s) using proper aseptic technique, typically avoiding contact between the dropper tip and the eye or any surface.

Serious risks include severe allergic reactions such as angio‑edema, marked systemic hypotension that can cause dizziness or fainting, and cardiac arrhythmias in susceptible patients. Any sudden visual changes, intense eye pain, or systemic symptoms should prompt immediate medical evaluation.

Iopidine® should not be used by individuals with known hypersensitivity to apraclonidine or any formulation component, and it is contraindicated in patients with severe cardiovascular instability where further blood pressure reduction could be harmful. Caution is also advised in pregnant or nursing women when safer alternatives exist.